Vascudyne is a regenerative medicine company dedicated to improving patient care through the development, manufacturing, and commercialization of regenerative acellular in-vitro grown allograft tissue. They offer a range of products and services that harness the power of nature-inspired biomaterials. Their TRUE™ Biomaterials are 100% biological soft tissue implants that provide numerous benefits.

These implants are non-immunogenic, non-calcific, and support cellular infiltration and tissue regeneration. Vascudyne's TRUE™ Tissue technology, currently under investigation, has the potential to revolutionize healthcare. Their products, such as TRUE™ Graft, have shown excellent performance in preclinical studies, with no evidence of thrombosis or intimal hyperplasia.

The allograft is derived from natural extracellular matrix, with no synthetic materials or chemical fixation used in the manufacturing process. It closely resembles and feels like natural tissue, offering high burst strength and predictable tensile properties. Vascudyne has also gained recognition in the industry, receiving the BioBusiness Award and being named a Top 3 Better World Project Award Finalist.

They continue to make advancements in regenerative medicine, recently announcing the successful first human use of TRUE™ Vascular Graft for hemodialysis access. To learn more or get in touch, visit their website today. Vascudyne is driven by a mission to transform patient care with regenerative biomaterials based on cutting-edge research and innovation